REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5 (b) - AbbVie Inc
RNS Number : 7427JBank of America Merrill Lynch15 April 2020FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1.
KEY INFORMATION
Name of exempt principal trader
BofA Securities, Inc.
Company dealt in
AbbVie Inc
Class of relevant security to which the
dealings being disclosed relate(Note 1)Common - US00287Y1091
Date of dealing
14/04/2020
2.
INTERESTS AND SHORT POSITIONS
(a)
Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common
US00287Y1091
Long
Short
Number
%
Number
%
(1)
Relevant securities
244,725
0.017%
2,482,185
0.168 %
(2)
Derivatives (other than options):
2,054,053
0.139%
147,526
0.01%
(3)
Options and agreements to purchase/sell:
7,400
0.001%
7,500
0.001%
Total
2,306,178
0.156%
2,637,211
0.179%
(b)
Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long
Short
Number
%
Number
%
(1)
Relevant securities
0
0%
0
0%
(2)
Derivatives (other than options):
0
0%
0
0%
(3)
Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3.
DEALINGS (Note 3)
(a)
Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Purchase
61,518
80.3 USD
Purchase
273
81.78 USD
Purchase
200
81.8 USD
Purchase
87
81.81 USD
Purchase
159
81.829 USD
Purchase
141
81.83 USD
Purchase
100
81.85 USD
Purchase
87
81.86 USD
Purchase
150
81.87 USD
Purchase
37
81.88 USD
Purchase
173
81.89 USD
Purchase
746
81.91 USD
Purchase
113
81.92 USD
Purchase
87
81.95 USD
Purchase
401
81.96 USD
Purchase
1
81.97 USD
Purchase
25
81.975 USD
Purchase
200
81.98 USD
Purchase
4
81.985 USD
Purchase
300
81.99 USD
Purchase
200
82 USD
Purchase
1
82.01 USD
Purchase
128
82.03 USD
Purchase
173
82.05 USD
Purchase
87
82.06 USD
Purchase
290
82.08 USD
Purchase
654
82.11 USD
Purchase
100
82.115 USD
Purchase
500
82.12 USD
Purchase
18,225
82.13 USD
Purchase
428
82.14 USD
Purchase
827
82.15 USD
Purchase
100
82.155 USD
Purchase
800
82.16 USD
Purchase
709
82.17 USD
Purchase
100
82.175 USD
Purchase
710
82.18 USD
Purchase
1,390
82.19 USD
Purchase
238
82.2 USD
Purchase
2
82.29 USD
Purchase
2
82.31 USD
Purchase
13
82.33 USD
Purchase
6
82.34 USD
Purchase
4
82.36 USD
Purchase
2
82.38 USD
Purchase
2
82.39 USD
Purchase
7
82.4 USD
Purchase
2
82.405 USD
Purchase
2
82.42 USD
Purchase
2
82.43 USD
Purchase
2
82.45 USD
Purchase
2
82.475 USD
Purchase
4
82.48 USD
Purchase
3
82.495 USD
Purchase
2
82.5 USD
Purchase
3
82.51 USD
Purchase
2
82.53 USD
Purchase
2
82.55 USD
Purchase
2
82.56 USD
Purchase
2
82.57 USD
Purchase
8
82.58 USD
Purchase
8
82.59 USD
Purchase
2
82.6 USD
Purchase
2
82.61 USD
Purchase
8
82.62 USD
Purchase
3
82.63 USD
Purchase
4
82.64 USD
Purchase
8
82.65 USD
Purchase
2
82.66 USD
Purchase
3
82.67 USD
Purchase
2
82.68 USD
Purchase
4
82.69 USD
Purchase
6
82.7 USD
Purchase
64
82.76 USD
Purchase
36
82.13 USD
Purchase
5,114
82.384 USD
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Sale
61,994
80.3 USD
Sale
1
81.45 USD
Sale
1
81.49 USD
Sale
401
81.56 USD
Sale
100
81.565 USD
Sale
300
81.57 USD
Sale
200
81.59 USD
Sale
200
81.595 USD
Sale
1
81.6 USD
Sale
100
81.61 USD
Sale
1
81.69 USD
Sale
13
81.75 USD
Sale
86
81.76 USD
Sale
200
81.765 USD
Sale
86
81.78 USD
Sale
100
81.79 USD
Sale
260
81.8 USD
Sale
386
81.81 USD
Sale
174
81.815 USD
Sale
2
81.82 USD
Sale
1
81.85 USD
Sale
1
81.87 USD
Sale
200
81.872 USD
Sale
156
81.89 USD
Sale
3
81.94 USD
Sale
1
81.95 USD
Sale
2
81.97 USD
Sale
1
81.98 USD
Sale
386
81.99 USD
Sale
783
82 USD
Sale
699
82.01 USD
Sale
22
82.02 USD
Sale
102
82.03 USD
Sale
19
82.04 USD
Sale
208
82.05 USD
Sale
493
82.06 USD
Sale
274
82.07 USD
Sale
100
82.09 USD
Sale
185
82.1 USD
Sale
126
82.11 USD
Sale
2
82.12 USD
Sale
478
82.13 USD
Sale
26
82.14 USD
Sale
68
82.141 USD
Sale
1
82.15 USD
Sale
156
82.16 USD
Sale
233
82.17 USD
Sale
649
82.18 USD
Sale
385
82.19 USD
Sale
757
82.2 USD
Sale
406
82.21 USD
Sale
530
82.22 USD
Sale
422
82.23 USD
Sale
176
82.24 USD
Sale
1
82.25 USD
Sale
739
82.26 USD
Sale
479
82.27 USD
Sale
2
82.275 USD
Sale
575
82.28 USD
Sale
469
82.29 USD
Sale
1
82.295 USD
Sale
1,078
82.3 USD
Sale
1,924
82.31 USD
Sale
86
82.315 USD
Sale
1,021
82.32 USD
Sale
89
82.325 USD
Sale
411
82.33 USD
Sale
9
82.335 USD
Sale
1,026
82.34 USD
Sale
100
82.345 USD
Sale
487
82.35 USD
Sale
202
82.36 USD
Sale
424
82.37 USD
Sale
19
82.38 USD
Sale
667
82.39 USD
Sale
100
82.4 USD
Sale
100
82.42 USD
Sale
7
82.43 USD
Sale
7
82.44 USD
Sale
7
82.46 USD
Sale
8
82.47 USD
Sale
1
82.49 USD
Sale
108
82.51 USD
Sale
87
82.52 USD
Sale
186
82.53 USD
Sale
95
82.54 USD
Sale
610
82.55 USD
Sale
406
82.56 USD
Sale
273
82.565 USD
Sale
17
82.57 USD
Sale
8
82.58 USD
Sale
7
82.59 USD
Sale
15
82.6 USD
Sale
139
82.61 USD
Sale
187
82.62 USD
Sale
7
82.63 USD
Sale
839
82.64 USD
Sale
169
82.65 USD
Sale
94
82.66 USD
Sale
102
82.67 USD
Sale
803
82.68 USD
Sale
570
82.69 USD
Sale
100
82.695 USD
Sale
354
82.7 USD
Sale
380
82.71 USD
Sale
100
82.72 USD
Sale
623
82.73 USD
Sale
100
82.74 USD
Sale
5
82.75 USD
Sale
2
82.76 USD
Sale
173
82.8 USD
Sale
157
82.11 USD
Sale
17,814
82.13 USD
Sale
200
82.15 USD
Sale
5,500
82.155 USD
Sale
200
82.16 USD
Sale
200
82.17 USD
Sale
100
82.175 USD
Sale
110
82.18 USD
Sale
490
82.19 USD
Sale
38
82.2 USD
(b)
Derivatives transactions (other than options transactions)
Product name,
e.g. CFDNature of transaction
(Note 5)Number of relevant securities
(Note 6)Price per unit
(Note 4)Swaps
Increasing a Long Position
129,175
80.3 USD
Swaps
Reducing a Short Position
42
82.14 USD
Swaps
Reducing a Short Position
26
82.14 USD
Swaps
Increasing a Long Position
353
82.13 USD
Swaps
Increasing a Long Position
200
81.871 USD
(c)
Options transactions in respect of existing relevant securities
(i)
Writing, selling, purchasing or varying
Product name, e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc
Expiry date
Option money paid/ received per unit (Note 4)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii)
Exercising
Product name,
e.g. call optionNumber of securities
Exercise price per
unit (Note 4)N/A
N/A
N/A
(d)
Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction
(Note 7)Details
Price per unit
(if applicable) (Note 4)
Borrow
Borrow of 463,000 shares
N/A
Borrow
Borrow of 137,700 shares
N/A
Borrow
Borrow of 17,800 shares
N/A
4.
OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.None
Is a Supplemental Form 38.5(b) attached? (Note 8)
YES
Date of disclosure
15/04/2020
Contact name
Tolu Tade
Telephone number
+44207 996 3410
Name of offeree/offeror with which connected
AbbVie Inc
Nature of connection (Note 9)
Advisor to - AbbVie Inc
SUPPLEMENTAL FORM 38.5(b)
DISCLOSURE UNDER RULE 38.5 (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DETAILS OF OPEN POSITIONS
Product name,
e.g. call optionWritten or
purchasedNumber of securities to which the option or derivative relates
Exercise price
(Note 2)Type, e.g.
American,
European etcExpiry date
Call Option
Written
7,500
105 USD
American
15/01/2021
Call Option
Purchased
7,400
85 USD
American
15/01/2021
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDISEBELFFBZLLBBL
Recent news on Abbvie
See all newsRCS - Ripple Therapeutics - Ripple Therapeutics Announces Collaboration
AnnouncementREG - Stock Exch Notice - Admission to ISM - 20/06/2024
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
Announcement